Patients on mepolizumab, benralizumab, or dupilumab have diminished post-vaccination antibody and B cell responses to SARS-CoV-2. - Milan 2023

Interactions at the host-environment interface governing the scale and phenotype of airway inflammation

Chair(s): Robert Snelgrove, Katharine Lodge

Session type: Oral presentation

Patients on mepolizumab, benralizumab, or dupilumab have diminished post-vaccination antibody and B cell responses to SARS-CoV-2.

Pedro Lamothe

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - Carnitine palmitoyltransferase 1A and its fatty acid oxidation as a protector of airway epithelial barrier

Muyun Wang

Replay

Poster

Abstract

Airway inflammation and hyperresponsiveness in asthma is regulated by the circadian clock through REV-ERB?

Amlan Chakraborty

Replay

Poster

Abstract

Slides

Epithelial alarmins enhance mast cell-dependent contractions of isolated human small bronchi

Maria Belikova

Replay

Poster

Abstract

Slides

Epithelium-derived cystatin SN inhibits HDM protease activity in allergic asthma

Xin Yao

Replay

Abstract

Slides

Neutrophilic responses in a subacute and chronic mouse model of pollutant-aggravated allergic asthma

Tania Maes

Replay

Poster

Abstract

Slides

Respiratory effects of cold air and diesel exposure in exercise-induced bronchoconstriction in mice

Nora Marain

Replay

Poster

Abstract

Slides

LSC - 2023 - Resolution of inflammation in long COVID

Sean Knight

Replay

Poster

Abstract

Slides

Patients on mepolizumab, benralizumab, or dupilumab have diminished post-vaccination antibody and B cell responses to SARS-CoV-2.

Pedro Lamothe

Replay

Poster

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}